TherapeuticsMD Capital Expenditures (CapEx) Growth & History (TXMD)
TherapeuticsMD's capital expenditures (capex) was $355,000 for fiscal 2022.
View full TherapeuticsMD company overviewTherapeuticsMD annual capital expenditures (capex) history
| Fiscal year | Period ended | Capital expenditures (CapEx) | Change | Growth |
|---|---|---|---|---|
| 2022 | 2022-12-31 | $355,000 | $321,000 | +944.12% |
| 2021 | 2021-12-31 | $34,000 | −$173,000 | −83.57% |
| 2020 | 2020-12-31 | $207,000 | −$2.2M | −91.55% |
| 2019 | 2019-12-31 | $2.5M | $2.2M | +1028.82% |
| 2018 | 2018-12-31 | $217,040 | $155,223 | +251.10% |
| 2017 | 2017-12-31 | $61,817 | −$334,337 | −84.40% |
| 2016 | 2016-12-31 | $396,154 | $230,897 | +139.72% |
| 2015 | 2015-12-31 | $165,257 | $134,295 | +433.74% |
| 2014 | 2014-12-31 | $30,962 | −$9,828 | −24.09% |
| 2013 | 2013-12-31 | $40,790 | −$25,615 | −38.57% |
| 2012 | 2012-12-31 | $66,405 | $37,639 | +130.85% |
| 2011 | 2011-12-31 | $28,766 | — | — |
TherapeuticsMD quarterly capital expenditures (capex)
| Fiscal quarter | Period ended | Capital expenditures (CapEx) | Change | YoY change |
|---|---|---|---|---|
| Q4 2022 | 2022-12-31 | $334,000 | $334,000 | — |
| Q3 2022 | 2022-09-30 | $0 | −$70,000 | — |
| Q2 2022 | 2022-06-30 | $21,000 | −$20,000 | −48.78% |
| Q1 2022 | 2022-03-31 | $42,000 | −$21,000 | −33.33% |
| Q4 2021 | 2021-12-31 | $0 | −$168,000 | — |
| Q3 2021 | 2021-09-30 | $70,000 | $57,000 | +438.46% |
| Q2 2021 | 2021-06-30 | $41,000 | $36,000 | +720.00% |
| Q1 2021 | 2021-03-31 | $63,000 | $42,000 | +200.00% |
| Q4 2020 | 2020-12-31 | $168,000 | −$192,587 | −53.41% |
| Q3 2020 | 2020-09-30 | $13,000 | −$983,909 | −98.70% |
| Q2 2020 | 2020-06-30 | $5,000 | −$825,086 | −99.40% |
| Q1 2020 | 2020-03-31 | $21,000 | −$241,418 | −92.00% |
| Q4 2019 | 2019-12-31 | $360,587 | $209,842 | +139.20% |
| Q3 2019 | 2019-09-30 | $996,909 | $976,334 | +4745.24% |
| Q2 2019 | 2019-06-30 | $830,086 | $811,274 | +4312.53% |
| Q1 2019 | 2019-03-31 | $262,418 | $235,510 | +875.24% |
| Q4 2018 | 2018-12-31 | $150,745 | $124,777 | +480.50% |
| Q3 2018 | 2018-09-30 | $20,575 | $20,575 | — |
| Q2 2018 | 2018-06-30 | $18,812 | $10,797 | +134.71% |
| Q1 2018 | 2018-03-31 | $26,908 | −$926 | −3.33% |
| Q4 2017 | 2017-12-31 | $25,968 | −$62,472 | −70.64% |
| Q3 2017 | 2017-09-30 | $0 | −$42,678 | — |
| Q2 2017 | 2017-06-30 | $8,015 | −$182,543 | −95.79% |
| Q1 2017 | 2017-03-31 | $27,834 | −$46,644 | −62.63% |
| Q4 2016 | 2016-12-31 | $88,440 | $1,975 | +2.28% |
| Q3 2016 | 2016-09-30 | $42,678 | $42,678 | — |
| Q2 2016 | 2016-06-30 | $190,558 | $148,619 | +354.37% |
| Q1 2016 | 2016-03-31 | $74,478 | $37,625 | +102.09% |
| Q4 2015 | 2015-12-31 | $86,465 | $86,465 | — |
| Q3 2015 | 2015-09-30 | $0 | $0 | — |
| Q2 2015 | 2015-06-30 | $41,939 | $34,669 | +476.88% |
| Q1 2015 | 2015-03-31 | $36,853 | $13,161 | +55.55% |
| Q4 2014 | 2014-12-31 | $0 | −$17,035 | — |
| Q3 2014 | 2014-09-30 | $0 | −$850 | — |
| Q2 2014 | 2014-06-30 | $7,270 | $7,270 | — |
| Q1 2014 | 2014-03-31 | $23,692 | $787 | +3.44% |
| Q4 2013 | 2013-12-31 | $17,035 | $14,536 | +581.67% |
| Q3 2013 | 2013-09-30 | $850 | −$1,650 | −66.00% |
| Q2 2013 | 2013-06-30 | $0 | −$34,018 | — |
| Q1 2013 | 2013-03-31 | $22,905 | −$9,481 | −29.27% |
| Q4 2012 | 2012-12-31 | $2,499 | $2,499 | — |
| Q3 2012 | 2012-09-30 | $2,500 | −$313 | −11.13% |
| Q2 2012 | 2012-06-30 | $34,018 | $18,978 | +126.18% |
| Q1 2012 | 2012-03-31 | $32,386 | $21,473 | +196.77% |
| Q4 2011 | 2011-12-31 | $0 | — | — |
| Q3 2011 | 2011-09-30 | $2,813 | — | — |
| Q2 2011 | 2011-06-30 | $15,040 | — | — |
| Q1 2011 | 2011-03-31 | $10,913 | — | — |
TherapeuticsMD capital expenditures (capex) trends
Over the last five fiscal years, TherapeuticsMD's capital expenditures (capex) increased from $61,817 to $355,000, a change of $293,183. The latest reported quarter, Q4 2022, shows $334,000.
What capital expenditures (CapEx) mean
Capital expenditures, commonly called CapEx, are cash investments in long-lived assets such as property, plants, equipment, infrastructure, and productive software. CapEx can support future growth or maintain existing operations, but it reduces current-period free cash flow.
SEC-reported capital expenditures
TickerStat standardizes cash payments for property, plant, equipment, and other productive assets reported in company SEC filings. When a filer reports separate qualifying CapEx components instead of a total, those components are combined for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review TherapeuticsMD source filings ↗